Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Capricor Therapeutics, Inc. CAPR

Healthcare — Biotechnology

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
8.37
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — 3 1 2 4 — — —
Insider Ownership
9.11%

Capital & Financial Ratios

Market Cap
558.14
Revenue
22.27
Net Income
(129.42)
Free Cash Flow
130.91
Net Debt
(237.93)
Current Ratio
7.35
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
23.57
P/B ratio
2.13
Past 5Y EPS Growth
11.01%
This Y EPS Growth
31.81%
Next Y EPS Growth
3.31%
Next 5Y EPS Growth
50.75%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2018 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 39.49 151.52 318.13 237.93
Receivables 10.37 10.37 0.06 —
Inventory — — — —
Other — — — —
50.86 163.39 322.94 242.13
2023 2024 2025 Q'26
Payables 6.25 3.28 1.65 3.08
ST’ Debt — — — —
Other — — 6.42 —
31.27 21.03 35.84 32.96
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 — — — —
—
’24 4.91 3.97 2.26 11.13
22.27
’23 2.99 3.92 6.19 12.09
25.18
’22 — — 1.59 0.96
2.55
’21 0.04 0.20 — 0.00
0.24
’20 0.19 0.05 0.02 0.06
0.31
’19 0.23 0.41 0.14 0.22
1.01
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (29.25) (31.49) — —
—
’25 (6.43) (20.12) (19.69) (23.57)
(69.81)
’24 (1.27) (12.29) (11.64) (14.80)
(40.00)
’23 4.21 (9.42) (8.79) (11.59)
(25.60)
’22 24.05 (6.54) (5.69) (6.90)
4.92
’21 (3.33) (4.51) (3.34) (5.63)
(16.81)
’20 (1.22) (2.02) (2.98) (3.84)
(10.05)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (40.00) (37.29) — —
—
’25 (7.57) (21.57) (23.70) 231.90
179.06
’24 (1.93) (12.37) (11.70) 78.27
52.26
’23 3.76 (9.65) (9.43) (12.32)
(27.64)
’22 23.42 (6.95) (6.78) (8.12)
1.56
’21 (3.37) (4.84) (3.81) (6.00)
(18.01)
’20 (1.22) (2.12) (3.13) (4.13)
(10.60)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.59) (0.70) — —
—
’25 (0.53) (0.57) (0.54) (0.62)
(2.26)
’24 (0.31) (0.35) (0.38) (0.16)
(1.15)
’23 (0.31) (0.29) (0.25) (0.02)
(0.83)
’22 (0.32) (0.29) (0.26) (0.31)
(1.18)
’21 (0.23) (0.21) (0.17) (0.26)
(0.87)
’20 (0.30) (0.23) (0.20) (0.21)
(0.88)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡

Recommendation Rating

2.2
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡ ‡‡‡‡ 2.56 2.68 3.52 4.30 — — —
Low Price
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡ 6.58 8.22 23.40 40.37 — — —
High Price
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 74 102 160 231 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.03 0.25 0.14 0.00 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.55 25.18 22.27 — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 100.00% 100.00% 100.00% — — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (29.02) (22.29) (40.47) (105.04) — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1,137.35%) (88.52%) (181.70%) 0.00% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (29.02) (22.29) (40.47) (105.04) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.53 1.07 1.43 1.89 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.10 0.94 0.63 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.18) (0.83) (1.15) (2.26) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.20 (0.96) (1.14) (1.50) — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.14) (0.08) 2.62 5.35 ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.06 (1.03) 1.48 3.85 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.48 0.84 4.13 6.58 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 24.55 26.78 35.22 46.48 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 34.30 5.45 21.82 — ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.02 6.07 3.34 — ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 21.43 4.11 15.28 — ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 37.92 (3.74) 6.51 — — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.92 (25.60) (40.00) (69.81) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.36) (2.05) 92.26 248.87 ‡‡‡‡‡ — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.56 (27.64) 52.26 179.06 — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 19.30 19.59 142.36 287.10 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.94 — — — — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (35.48) (39.49) (151.52) (318.13) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 11.79 22.60 145.46 305.79 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (63.48%) (40.96%) (35.31%) (39.91%) — — —
ROA
‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ 0.00% 0.00% 0.00% 0.00% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (134.49%) (129.63%) (48.16%) (46.56%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Capricor Therapeutics (CAPR), a clinical-stage biotech targeting Duchenne muscular dystrophy with its lead candidate deramiocel (CAP-1002), exemplifies high-risk biotech volatility. Recent Phase 3 HOPE-3 trial data showed statistically significant respiratory improvements (p=0.002), earning FDA Breakthrough Therapy Designation and fueling explosive revenue forecasts: a 97% drop to $0.59M in 2025, then surging 21,566% to $127.8M in 2026 and $160.4M in 2027 on potential approval and launch. Revenue per share could hit $3.10 by 2027 from $0.63 in 2024, with stock targets implying 82-176% upside amid a 1,590% rebound from 2020 lows.

Yet, chronic challenges persist: cumulative losses over $200M through 2024, operating cash outflows of -$40M, and shares outstanding up 1,797% since 2016 due to dilution. Profitability remains elusive (EBT margin -1.82% in 2024), efficiency metrics like revenue per employee vary wildly ($5K to $139K), and a 2025 “valley of death” risks further burns despite $151M net cash buffer covering 3-4 years.

CAPR tempts with 100%+ gains in a $10B+ DMD market but faces 50-70% approval odds, competition from gene therapies like Elevidys, zero insider buys, and historical crashes on setbacks. Position sizing below 5% advised until milestones prove out—read the full analysis for detailed models and risk quantifications.

Read full commentary →

Capricor Therapeutics, Inc. (CAPR) Latest News

News by impact score

Fine-tune

7 Sep

4 , 9:28 AM
CAPR stock rose 144% over the past month on positive company developments driving investor buying. Major positive developments have produced sharp stock gains that signal substantially improved company prospects.

4 Sep

4 , 8:44 PM
New long-term data on Capricor Therapeutics' Duchenne muscular dystrophy therapy may strengthen clinical support and advance development prospects for the treatment. Long-term data on core Duchenne therapy can drive major shifts in Capricor's clinical progress and investor sentiment.

1 Sep

3 investorshub.advfn.com, 6:55 AM
Capricor Therapeutics shares rose 2.5% after an August FDA update. FDA update triggered modest 2.5% share gain reflecting limited but noticeable regulatory effect on company outlook.

3 stocktwits.com, 6:52 AM
CAPR stock rises as Piper Sandler cites favorable risk-reward for holding shares into upcoming FDA decision. Analyst endorsement ahead of FDA decision can moderately shift short-term investor sentiment and stock movement.

27 Aug

4 , 10:25 AM
Capricor (CAPR) faces a narrower path after a rejected vote limits its options and development prospects. Rejected vote directly constrains Capricor's strategic options and future performance.

24 Aug

4 stocktwits.com, 5:02 PM
CAPR stock climbs after FDA grants three-month Deramiocel review extension. HC Wainwright maintains neutral rating and flags high rejection risk. FDA extension and high rejection risk for Deramiocel directly shift CAPR approval timeline and market trajectory.

4 stocktwits.com, 10:33 AM
CAPR shares rise after announcement of positive phase 2 trial results for its Duchenne muscular dystrophy cell therapy showing improved cardiac outcomes and advancing toward later-stage development. Positive clinical data signals major pipeline progress that can drive valuation and strategic positioning.

4 , 9:25 AM
FDA extends PDUFA target action date for Capricor Therapeutics' Deramiocel BLA as review continues. Extension delays potential approval of lead product Deramiocel and affects Capricor Therapeutics valuation.

3 investorshub.advfn.com, 10:05 AM
FDA extends Capricor Therapeutics Deramiocel PDUFA date to November while reviewing BLA amendment. PDUFA extension delays approval decision for lead candidate and may shift near-term regulatory and financial outlook.

3 www.biopharmadive.com, 7:30 AM
FDA extends review of Capricor cell therapy. Pain drug startup to go public. FDA review extension delays cell therapy approval timeline and affects investor sentiment for Capricor.

21 Aug

4 stocktwits.com, 6:48 PM
Capricor Therapeutics stock sinks as investors brace for imminent FDA decision on Deramiocel. Imminent FDA decision on Deramiocel can substantially alter Capricor Therapeutics' trajectory and investor sentiment.

4 stocktwits.com, 11:00 AM
Kaos Capital is pushing for a board shakeup at Capricor Therapeutics ahead of an FDA decision on its DMD therapy, drawing investor attention to the company. Shareholder activism targeting board composition before a pivotal FDA ruling may shift governance and drive notable stock movement.

3 , 7:45 AM
Kaos Capital calls on Capricor Therapeutics (NASDAQ: CAPR) shareholders to take action on company matters. Activist investor outreach to shareholders signals potential governance or strategic shifts with moderate market impact.

3 , 7:45 AM
Kaos Capital calls on Capricor (NASDAQ: CAPR) shareholders, urging action on company matters that could influence strategy or governance. Activist investor involvement may pressure management and shift short-term sentiment without guaranteed long-term changes.

20 Aug

4 transcript www.fool.com, 6:28 PM
Capricor Therapeutics held its Q2 2026 earnings call to report financial results and provide operational updates. Earnings call delivers key financial and clinical updates that typically shift investor sentiment and stock trajectory.

19 Aug

4 , 8:31 PM
Capricor Therapeutics stock surged 58% after receiving an FDA lifeline, raising questions on whether regulatory approval is back on track. FDA lifeline represents major regulatory development that could significantly alter Capricor's trajectory and investor sentiment.

15 Aug

4 , 6:10 AM
Capricor Therapeutics (CAPR) shares rise 62.6% despite mounting FDA scrutiny and lawsuits over Deramiocel. FDA scrutiny and lawsuits create major regulatory and legal risks that can alter company trajectory.

3 transcript app.moby.co, 8:30 AM
Capricor Therapeutics reported Q2 2026 financial results and operational updates in its earnings call. Quarterly earnings call delivers financial metrics and guidance with moderate effects on near-term sentiment and operations.

14 Aug

4 stocktwits.com, 6:18 AM
Cantor Fitzgerald turns bullish on Capricor Therapeutics with a 278% upside target tied to Deramiocel FDA approval path, sending CAPR stock surging premarket. Analyst upgrade with 278% upside on Deramiocel FDA path triggers sharp premarket rally and elevates company trajectory.

4 www.biopharmadive.com, 5:28 AM
Capricor Therapeutics shares spiked after CEO comments. Cytokinetics sued Bristol Myers. CEO comments drove immediate share price spike with clear market reaction for CAPR.

4 transcript , 1:03 AM
Capricor Therapeutics reported Q2 2026 earnings while addressing an FDA setback that delays its clinical programs and regulatory path. FDA setback creates significant regulatory delay and alters Capricor's development timeline and market outlook.

13 Aug

4 stocktwits.com, 7:32 PM
CAPR shares jumped 67% after hours on Deramiocel updates, leaving open questions on development path and regulatory prospects. 67% after-hours surge signals major regulatory or clinical progress that can materially shift company trajectory and sentiment.

3 transcript www.marketbeat.com, 7:04 PM
Capricor Therapeutics Q2 earnings call highlights financial results and operational updates. Q2 earnings call updates investors on company's financial status and future outlook.

3 , 4:05 PM
Capricor Therapeutics reported second quarter 2026 financial results along with a corporate update. Quarterly earnings releases deliver performance metrics that can shift near-term investor sentiment for the company.

12 Aug

4 , 1:41 AM
Capricor Therapeutics (CAPR) stock fair value falls after Deramiocel AdCom setback. Deramiocel AdCom setback reduces Capricor Therapeutics stock value and alters future market trajectory.

31 Jul

4 stocktwits.com, 1:42 PM
CAPR stock heads for worst week ever after regulatory setback on DMD therapy. Regulatory setback for core DMD therapy drives CAPR stock toward worst week on record.

30 Jul

4 , 9:30 AM
Capricor Therapeutics provided an update on the FDA Advisory Committee Meeting for Deramiocel. FDA advisory outcome on Deramiocel directly affects approval chances and company trajectory.

4 stocktwits.com, 7:58 AM
Wall Street analysts split on Capricor FDA outcome with one forecasting $2 stock price while retail investors hold out hope for positive resolution. FDA regulatory decision directly determines Capricor product approval and long-term company valuation trajectory.

29 Jul

5 stocktwits.com, 4:24 PM
Capricor Therapeutics faces a pivotal FDA advisory panel review for its Duchenne muscular dystrophy cell therapy, with experts and investors assessing approval prospects and company outlook. Make-or-break FDA panel outcome on core Duchenne therapy can determine product approval, revenue potential, and long-term company viability.

4 stocktwits.com, 11:07 PM
Capricor Therapeutics stock heads for its worst week ever after an FDA panel rejection of Deramiocel, though retail bulls still expect eventual approval. FDA panel rejection of lead asset Deramiocel creates major regulatory setback for Capricor approval path and stock trajectory.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us